Latest Content
Recent years have seen significant developments in the landscape of cell and gene therapies, with a notable increase in treatments available for rare and life-threatening diseases. These advancements come despite the generally high costs of research,...
Read More
As part of Evaluate’s partnership with Galen Growth, we bring you their latest report on Digital Health Innovation in US Health Systems, built using data from HealthTech Alpha.
In the vast and complex US healthcare system, it’s challenging for all types...
Read More
Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity’s, emerges from years of underinvestment, resulting in a landscape filled...
Read More
